Metabolic Associated Fatty Liver Disease with prediabetes.
Conditions
Brief summary
Significant decrease in the amount of intrahepatic fat (> 20%) in the absence of liver fibrosis progression.
Detailed description
Study of insulin resistance and adipose tissue dysfunction, Search for non-invasive markers of efficacy of the proposed treatments among circulating metabolites (metabolomic and lipidomic methods)., Study of the intestinal microbiota., Pharmacogenetic study: influence of genetic variations on the degree of therapeutic response to drugs., Study of bioimpedanciometry., Collection of adverse events potentially related to the medication and its administration.
Interventions
DRUGPioglitazone Holsten 15 mg tabletter
DRUGMetformin Hydrochloride 500mg Tablets
Sponsors
Consorcio Centro De Investigacion Biomedica En Red
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Study of insulin resistance and adipose tissue dysfunction, Search for non-invasive markers of efficacy of the proposed treatments among circulating metabolites (metabolomic and lipidomic methods)., Study of the intestinal microbiota., Pharmacogenetic study: influence of genetic variations on the degree of therapeutic response to drugs., Study of bioimpedanciometry., Collection of adverse events potentially related to the medication and its administration. | — |
Primary
| Measure | Time frame |
|---|---|
| Significant decrease in the amount of intrahepatic fat (> 20%) in the absence of liver fibrosis progression. | — |
Countries
Spain
Outcome results
None listed